Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Creatinine kinase BB (CK-BB) is elevated in many tumours including those of the breast. We have recently described a new, highly sensitive and specific method for measuring CK-BB, based on monoclonal antibodies and time-resolved fluorometry. Using this method, we quantitated CK-BB in 172 breast tumour cytosols and examined the associations between CK-BB and other clinicopathological variables and patient survival. High CK-BB levels were seen more frequently in tumours from patients who were younger (age < 50 years), patients who qualified for chemotherapy and patients with oestrogen receptor-positive tumours. No association was seen between CK-BB and tumour stage, grade, size, histological type or the progesterone receptor. In univariate analysis, the risk of relapse or death was higher in the group with tumours containing high CK-BB levels but the difference did not reach statistical significance. In multivariate analysis, the risk of death was statistically significantly higher in the high-CK-BB group. Analysis of subsets of patients revealed that patients with oestrogen receptor-negative cancer have higher risk of death if their tumours contain high levels of CK-BB. Our data suggest that, in general, CK-BB is associated with more aggressive tumours but its value as a prognostic indicator is limited. CK-BB content of breast tumours may be more useful as an aid in selecting therapy directed at inhibiting this enzyme activity and thus depriving tumour cells of their energy source.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wallimann, T., Wyss, M., Brdiczka, D., Nicolay, K., & Eppenberger, H. M. (1992) · Biochemical Journal · doi:10.1042/bj2810021 · Cited by 2,011
Cited by
Creatine and Creatinine Metabolism
Wyss, M., & Kaddurah-Daouk, R. (2000) · Physiological Reviews · doi:10.1152/physrev.2000.80.3.1107 · Cited by 2,950
Durany, N., Joseph, J., Jimenez, O. M., Climent, F., Fernández, P. L., Rivera, F., & Carreras, J. (2000) · British Journal of Cancer · doi:10.1054/bjoc.1999.0871 · Cited by 76
Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis
Li, X.-H., Chen, X.-J., Ou, W.-B., Zhang, Q., Lv, Z.-R., Zhan, Y., Ma, L., Huang, T., Yan, Y.-B., & Zhou, H.-M. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.02.003 · Cited by 74
“Particularly, CKB has been found to be overexpressed in several types of cancers including breast cancer, colorectal cancer, colon cancer, and ovarian cancer (Balasubramani et al., 2006; Huddleston et al., 2005; Mooney et al., 2011; Wallimann and Hemmer, 1994; Zarghami et al., 1996).”
BackgroundHuddleston, H. G., Wong, K.-K., Welch, W. R., Berkowitz, R. S., & Mok, S. C. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.08.047 · Cited by 68
Patra, S., Ghosh, A., Roy, S. S., Bera, S., Das, M., Talukdar, D., Ray, S., Wallimann, T., & Ray, M. (2012) · Amino Acids · doi:10.1007/s00726-011-0974-3 · Cited by 64
Metadata
- Authors
- Zarghami, N., Giai, M., Yu, H., Roagna, R., Ponzone, R., Katsaros, D., Sismondi, P., & Diamandis, E.
- Venue
- British Journal of Cancer
- Published
- 1996-02
- Volume
- 73
- Issue
- 3
- Pages
- 386-390
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2052913806
- Cited by
- 55
- References
- 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. https://app.cochat.ai/papers/10.1038/bjc.1996.66
- The paper
- Zarghami, N., Giai, M., Yu, H., Roagna, R., Ponzone, R., Katsaros, D., Sismondi, P., & Diamandis, E. (1996). Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. British Journal of Cancer. https://doi.org/10.1038/bjc.1996.66
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.